ImmunoGen Inc. (IMGN)

3.31
NASDAQ : Health Technology
Prev Close 3.13
Day Low/High 3.10 / 3.35
52 Wk Low/High 1.76 / 9.84
Avg Volume 2.42M
Exchange NASDAQ
Shares Outstanding 149.88M
Market Cap 469.14M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

IMGN Crosses Above Average Analyst Target

IMGN Crosses Above Average Analyst Target

In recent trading, shares of ImmunoGen, Inc. have crossed above the average analyst 12-month target price of $2.75, changing hands for $2.80/share.

ImmunoGen Reports Recent Progress And Second Quarter 2019 Financial Results

ImmunoGen Reports Recent Progress And Second Quarter 2019 Financial Results

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2019.

ImmunoGen Announces Conference Call To Discuss Its Second Quarter 2019 Operating Results

ImmunoGen Announces Conference Call To Discuss Its Second Quarter 2019 Operating Results

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.

ImmunoGen Announces Completion Of Operational Review

ImmunoGen Announces Completion Of Operational Review

ImmunoGen, Inc., (Nasdaq:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the completion of an in-depth operational review designed to extend the Company's cash runway and deliver on...

ImmunoGen Announces Mature Data From FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine In Combination With Avastin® In Ovarian Cancer

ImmunoGen Announces Mature Data From FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine In Combination With Avastin® In Ovarian Cancer

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced mature data from the FORWARD II expansion cohort evaluating mirvetuximab soravtansine in combination with...

ImmunoGen Plunges as FDA Rejects Fast-Track Approval for Cancer Drug

ImmunoGen Plunges as FDA Rejects Fast-Track Approval for Cancer Drug

Shares of ImmunoGen plunge after the U.S. Food and Drug Administration requests additional trials to 'evaluate the safety and efficacy' of one of its cancer-fighting treatments.

ImmunoGen Provides Regulatory Update On Mirvetuximab Soravtansine Monotherapy In Ovarian Cancer

ImmunoGen Provides Regulatory Update On Mirvetuximab Soravtansine Monotherapy In Ovarian Cancer

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the United States Food and Drug Administration (FDA) has recommended that the Company conduct a new Phase 3...

ImmunoGen Reports Recent Progress And First Quarter 2019 Financial Results

ImmunoGen Reports Recent Progress And First Quarter 2019 Financial Results

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2019.

ImmunoGen Announces Conference Call To Discuss Its First Quarter 2019 Operating Results

ImmunoGen Announces Conference Call To Discuss Its First Quarter 2019 Operating Results

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.

Immunogen Tanks After Ovarian Cancer Drug Study Fails to Meet Endpoint

Immunogen Tanks After Ovarian Cancer Drug Study Fails to Meet Endpoint

Immunogen's cancer treatment candidate fails to meet the primary endpoint in a phase 3 trial.

ImmunoGen Announces Top-Line Results From Phase 3 FORWARD I Study Of Mirvetuximab Soravtansine In Ovarian Cancer

ImmunoGen Announces Top-Line Results From Phase 3 FORWARD I Study Of Mirvetuximab Soravtansine In Ovarian Cancer

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that its Phase 3 FORWARD I trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to...

ImmunoGen Announces Multiple Presentations At AACR Annual Meeting

ImmunoGen Announces Multiple Presentations At AACR Annual Meeting

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that 11 posters highlighting continued innovation in the field of ADCs will be presented at the upcoming...

Noteworthy Wednesday Option Activity: IMGN, WATT, SGRY

Noteworthy Wednesday Option Activity: IMGN, WATT, SGRY

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ImmunoGen, Inc. , where a total of 40,874 contracts have traded so far, representing approximately 4.1 million underlying shares.

ImmunoGen Announces Sale Of Residual Kadcyla Royalties

ImmunoGen Announces Sale Of Residual Kadcyla Royalties

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the sale of its residual rights to receive royalty payments on commercial sales of Kadcyla ® (ado-trastuzumab...

First Week Of February 15th Options Trading For ImmunoGen (IMGN)

First Week Of February 15th Options Trading For ImmunoGen (IMGN)

Investors in ImmunoGen, Inc. saw new options become available this week, for the February 15th expiration.

ImmunoGen Announces Webcast Of Presentation And Q&A At The 37th Annual J.P. Morgan Healthcare Conference

ImmunoGen Announces Webcast Of Presentation And Q&A At The 37th Annual J.P. Morgan Healthcare Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 37 th Annual J.

ImmunoGen Becomes Oversold (IMGN)

ImmunoGen Becomes Oversold (IMGN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

ImmunoGen Presents New Data Highlighting Potential Of Novel ADCs In Oral Presentations At ASH Annual Meeting

ImmunoGen Presents New Data Highlighting Potential Of Novel ADCs In Oral Presentations At ASH Annual Meeting

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new data from the ongoing Phase 1 studies of IMGN632 and IMGN779, next-generation CD123- and...

ImmunoGen Announces Resignation Of Chief Financial Officer

ImmunoGen Announces Resignation Of Chief Financial Officer

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that David B.

First Week Of IMGN July 2019 Options Trading

First Week Of IMGN July 2019 Options Trading

Investors in ImmunoGen, Inc. saw new options begin trading this week, for the July 2019 expiration.

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:...

ImmunoGen Reports Recent Progress And Third Quarter 2018 Operating Results

ImmunoGen Reports Recent Progress And Third Quarter 2018 Operating Results

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported operating results for the quarter ended September 30, 2018.

ImmunoGen To Present New Data On Novel Antibody-Drug Conjugates At 60th ASH Annual Meeting

ImmunoGen To Present New Data On Novel Antibody-Drug Conjugates At 60th ASH Annual Meeting

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that abstracts highlighting two of the Company's experimental ADC therapies, IMGN779 and IMGN632, have been...

Interesting IMGN Put And Call Options For December 21st

Interesting IMGN Put And Call Options For December 21st

Investors in ImmunoGen, Inc. saw new options become available this week, for the December 21st expiration.

Oversold Conditions For ImmunoGen (IMGN)

Oversold Conditions For ImmunoGen (IMGN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

ImmunoGen Presents Initial Data From FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine In Combination With KEYTRUDA At ESMO 2018 Congress

ImmunoGen Presents Initial Data From FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine In Combination With KEYTRUDA At ESMO 2018 Congress

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab...

ImmunoGen Announces Conference Call To Discuss Its Third Quarter 2018 Operating Results

ImmunoGen Announces Conference Call To Discuss Its Third Quarter 2018 Operating Results

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.

ImmunoGen To Present Initial Data From FORWARD II Expansion Cohort Of Mirvetuximab Soravtansine In Combination With KEYTRUDA At ESMO

ImmunoGen To Present Initial Data From FORWARD II Expansion Cohort Of Mirvetuximab Soravtansine In Combination With KEYTRUDA At ESMO

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that initial findings from the FORWARD II expansion cohort of mirvetuximab soravtansine in combination with...

TheStreet Quant Rating: D (Sell)